BPC-157 Reverses Chronic Amphetamine-Induced Behavioral Disturbances in Rats
BPC-157 attenuated tolerance, sensitization, and withdrawal behaviors from chronic amphetamine exposure in rats, demonstrating comprehensive protection against stimulant drug-induced brain changes.
Quick Facts
What This Study Found
BPC-157 attenuated chronic amphetamine-induced tolerance, behavioral sensitization, and withdrawal disturbances in rats, demonstrating comprehensive dopamine system stabilization against stimulant drug-induced neuroplasticity.
Key Numbers
How They Did This
Animal study in rats with chronic amphetamine exposure. BPC-157 co-administered at microgram and nanogram doses. Tolerance, sensitization (cross-sensitization), and withdrawal behaviors measured across multiple timepoints.
Why This Research Matters
Stimulant addiction (amphetamine, methamphetamine) is devastating and has limited treatments. A peptide that comprehensively protects against chronic stimulant brain changes could transform addiction medicine.
The Bigger Picture
BPC-157's ability to stabilize the dopamine system against chronic stimulant disruption is consistent with its broader neuroprotective profile. A dopamine stabilizer rather than a blocker or agonist represents a novel addiction treatment concept.
What This Study Doesn't Tell Us
Rat model. Chronic amphetamine differs from human addiction patterns. The specific dopamine system mechanisms were not fully characterized.
Questions This Raises
- ?Could BPC-157 help methamphetamine addiction treatment?
- ?Does it work after addiction is established or only preventively?
- ?What is the molecular mechanism of BPC-157's dopamine stabilization?
Trust & Context
- Key Stat:
- Triple protection BPC-157 attenuated tolerance AND sensitization AND withdrawal from chronic amphetamine — comprehensive protection against all stimulant-induced brain changes
- Evidence Grade:
- Preliminary animal evidence with comprehensive behavioral characterization across multiple chronic amphetamine effects and two BPC-157 dose levels.
- Study Age:
- Published in 2002. BPC-157's dopamine-stabilizing and neuroprotective effects have been further confirmed in subsequent addiction and neuropharmacology studies.
- Original Title:
- Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.
- Published In:
- Acta pharmacologica Sinica, 23(5), 412-22 (2002)
- Authors:
- Sikiric, Predrag(44), Jelovac, Nikola(3), Jelovac-Gjeldum, Andjelka, Dodig, Goran, Staresinic, Mario, Anic, Tomislav, Zoricic, Ivan, Rak, Davor, Perovic, Darko, Aralica, Gorana, Buljat, Gojko, Prkacin, Ingrid, Lovric-Bencic, Martina, Separovic, Jadranka, Seiwerth, Sven, Rucman, Rudolf, Petek, Marijan, Turkovic, Branko, Ziger, Tihomil, Boban-Blagaic, Alenka, Bedekovic, Vlado, Tonkic, Ante, Babic, Slaven
- Database ID:
- RPEP-00771
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can BPC-157 help with stimulant addiction?
In rats, it protected against all the brain changes caused by chronic amphetamine: tolerance (needing more drug), sensitization (enhanced certain responses), and withdrawal symptoms. This is remarkable comprehensive protection.
How does it work differently from other addiction drugs?
Most addiction drugs either block dopamine (causing their own side effects) or substitute for the drug. BPC-157 appears to stabilize the dopamine system — keeping it functioning normally despite the drug's disruption. This is a fundamentally different, potentially better approach.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00771APA
Sikiric, Predrag; Jelovac, Nikola; Jelovac-Gjeldum, Andjelka; Dodig, Goran; Staresinic, Mario; Anic, Tomislav; Zoricic, Ivan; Rak, Davor; Perovic, Darko; Aralica, Gorana; Buljat, Gojko; Prkacin, Ingrid; Lovric-Bencic, Martina; Separovic, Jadranka; Seiwerth, Sven; Rucman, Rudolf; Petek, Marijan; Turkovic, Branko; Ziger, Tihomil; Boban-Blagaic, Alenka; Bedekovic, Vlado; Tonkic, Ante; Babic, Slaven. (2002). Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.. Acta pharmacologica Sinica, 23(5), 412-22.
MLA
Sikiric, Predrag, et al. "Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.." Acta pharmacologica Sinica, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Pentadecapeptide BPC 157 attenuates chronic amphetamine-indu..." RPEP-00771. Retrieved from https://rethinkpeptides.com/research/sikiric-2002-pentadecapeptide-bpc-157-attenuates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.